Evogene Ltd.

Stage 4 · Declining · week 4

As of Oct 22, 2026, Evogene is in Stage 4, the downtrend phase, now in week 4 (since Oct 1, 2026). It closed at $0.38, 71.3% below its 52-week high and below its 200-day average, which is falling.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. More about the company

$0.38

+1.48% today

$5.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is EVGN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 56w

S4 43w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 4w → S4 10w → S1 5w → S2 10w → S3 8w → S4 1w → S3 1w → S4 56w → S1 9w → S4 9w → S1 1w → S4 43w → S1 3w → S4 3w current

Total tracked: 165 weeks across 15 stage runs.

EVGN among Biotechnology424th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…424	EVGNEvogene Ltd.	Stage 4 · wk 4	15	−16.5%

vs 52W High

-71.3%

$0.37 lo$1.31 hi

71.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-45.1%

200 DMA: $0.69 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.5%

-30.4%

-52.4%

YTD

-66.7%

-71.1%

Scan Membership

Breakout Watch

Latest: 2024-01-16

3 appearances in last 60 days. First seen: 2020-09-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 4 · Vol 0.01x

2026-10-21S4

Wk 3 · Vol 0.02x

2026-10-20S4

Wk 3 · Vol 0.01x

2026-10-19S4

Wk 3 · Vol 0.07x

2026-10-16S4

Wk 3 · Vol 0.02x

2026-10-15S4

Wk 3 · Vol 0.02x

2026-10-14S4

Wk 2 · Vol 0.03x

2026-10-13S4

Wk 2 · Vol 0.05x

2026-10-12S4

Wk 2 · Vol 0.06x

2026-10-09S4

Wk 2 · Vol 0.06x

2026-10-08S4

Wk 2 · Vol 0.05x

2026-10-07S4

Wk 1 · Vol 0.05x

Moving averages & range

50 DMA

$0.48

200 DMA

$0.69

52W High

$1.31

52W Low

$0.37

5D Low

$0.37

Resistance levels (recent highs)

20d High

$0.44

60d High

$0.70

120d High

$0.79

250d High

$1.31

Next resistance

+17.1%

to 20d High

ROE

-182.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -1.5

Evogene: quick answers

What stage is Evogene in?

As of Oct 22, 2026, Evogene (EVGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Evogene in an uptrend?

No. Evogene is in a Stage 4 downtrend. It trades 45.1% below its 200-day average, which is falling.

How far is Evogene from its 52-week high?

Evogene closed at $0.38 on Oct 22, 2026, 71.3% below its 52-week high of $1.31. Its 52-week low is $0.37.

How has Evogene performed over the past year?

As of Oct 22, 2026, Evogene is down 71.1% over the past year and down 66.7% so far in 2026.

Which sector and industry is Evogene in?

Evogene is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.